Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you operate or are building an FDA-licensed outsourcing facility, this funds both expansion to fill drug shortages and anti-fraud infrastructure.
Report stale or inaccurate summary
What this is
This FDA opportunity targets outsourcing facilities—contract manufacturers and compounders—that can help address drug shortages by scaling production of needed medicines. The funding emphasizes both fraud prevention (likely anti-counterfeiting, supply chain integrity) and operational support to remove regulatory or logistical bottlenecks. This is relevant to manufacturers, biotech firms, and facility operators already licensed or pursuing FDA authorization to produce pharmaceuticals.
Who can apply
Likely restricted to licensed or licensable outsourcing facilities, compounders, and contract manufacturers already operating under FDA oversight or capable of meeting cGMP standards. Solo founders and very early-stage startups without manufacturing capability or FDA pathway are unlikely to qualify; established small-to-medium manufacturers with pharmaceutical production experience are the primary audience.
Topics: drug shortage · outsourcing facility · pharmaceutical manufacturing · fraud prevention · FDA compliance · compounding · supply chain integrity
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.